Table 1.

Top performing mAbs for MARV from human survivors.

	Antibody and Source	Target	Competes with	Cross-Binds	Cross Neutralizes	Protection	Reference
MR72	Human IgG1; Survivor from 2014 MARV outbreak in Uganda	Receptor-binding site (RBS) near the hydrophobic trough and the apex of GP1	MR78, MR82, MR191	MARV (all strains), EBOV GP	MARV (Uganda), RAVV	100% protective in mice (n = 5) against MARV (Uganda) in mice	[95]
M78	Human IgG1; Survivor from 2014 MARV outbreak in Uganda	Binds to the top and side of GP1 at a shallow angle relative to the central three-fold axis	MR72, MR82, MR191	MARV (Uganda) and RAVV	MARV (Uganda and Ravn), potentially neutralizes EBOV entry by inhibiting viral membrane fusion downstream from virus receptor recognition	100% protective in guinea pigs against MARV (Angola) and 100% against RAVV	[95,97]
MR82	Human IgG1; Survivor from 2014 MARV outbreak in Uganda	Binds toward the top and side of GP1 at a shallow angle relative to the central three-fold axis	MR72, MR78, MR191	MARV (all strains)	MARV (all strains)	40% protective in guinea pigs; however, it was 100% effective in mice	[95]
MR191	Human IgG1; Survivor from 2014 MARV outbreak in Uganda	RBS near the hydrophobic trough and the apex of GP1	MR72, MR78, MR82	MARV (Muskoke and Angola), RAVV, EBOV GP (does not neutralize)	MARV (Angola and Muskoke)	100% protective against MARV (Angola) and RAVV in guinea pigs. 100% effective in NHPs when treated on day 4 and 7 post infection (MARV Angola). 80% protective on days 5 and 8 post infection of RAVV. Did not protect against GPA-SUDV in guinea pig models 3 dpi	[94,95,98]